atomoxetine + Stimulants
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cerebrovascular Accident
Conditions
Cerebrovascular Accident, Transient Ischemic Attack, ADHD
Trial Timeline
Jan 1, 2008 → Sep 1, 2008
NCT ID
NCT00634439About atomoxetine + Stimulants
atomoxetine + Stimulants is a pre-clinical stage product being developed by Eli Lilly for Cerebrovascular Accident. The current trial status is completed. This product is registered under clinical trial identifier NCT00634439. Target conditions include Cerebrovascular Accident, Transient Ischemic Attack, ADHD.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00634439 | Pre-clinical | Completed |
Competing Products
14 competing products in Cerebrovascular Accident
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM872 (zonampanel) | Astellas Pharma | Phase 2 | 52 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 85 |
| ONO-2506 | Ono Pharmaceutical | Phase 2/3 | 65 |
| Abciximab | Eli Lilly | Phase 3 | 77 |
| ticagrelor + ASA + Placebo+ASA | AstraZeneca | Approved | 85 |
| Valsartan | Novartis | Pre-clinical | 23 |
| Atorvastatin | Pfizer | Approved | 84 |
| Rivaroxaban | Bayer | Pre-clinical | 20 |
| Darolutamide (BAY1841788) + Enzalutamide | Bayer | Phase 1 | 30 |
| Botulinum toxin type A + Placebo | Ipsen | Approved | 82 |
| Atorvastatin 20mg | Brain Biotech | Approved | 77 |
| Autologous bone marrow mononuclear cell transplantation | Brain Biotech | Phase 1 | 25 |
| Roflumilast Oral Tablet | Brain Biotech | Phase 2 | 44 |